US 12,454,547 B2
Steroidal compositions and methods of treating lipogenic cancers
Antonio Feula, San Mateo, CA (US); Francesco G Salituro, Marlborough, MA (US); and Ryan Edward Stites, Indianapolis, IN (US)
Assigned to Asteroid Therapeutics, Indianapolis, IN (US)
Filed by Asteroid Therapeutics, Indianapolis, IN (US)
Filed on Apr. 22, 2023, as Appl. No. 18/305,332.
Claims priority of provisional application 63/486,681, filed on Feb. 24, 2023.
Claims priority of provisional application 63/363,399, filed on Apr. 22, 2022.
Prior Publication US 2023/0340011 A1, Oct. 26, 2023
Int. Cl. C07J 41/00 (2006.01); A61P 35/00 (2006.01); C07J 9/00 (2006.01); C07J 43/00 (2006.01)
CPC C07J 41/0061 (2013.01) [A61P 35/00 (2018.01); C07J 9/00 (2013.01); C07J 43/003 (2013.01)] 6 Claims
 
1. A compound of Formula IIa or a stereoisomer or pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
R6 is R6C (wherein * is the point of attachment to formula I):

OG Complex Work Unit Chemistry
Q is absent or is O;
n is selected from 0, 1, 2, and 3;
p is selected from 0, 1, 2, and 3, provided that in R6C, when Q is absent, then n+p total at least 2;
Het(Ar) is selected from the group pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,2-thiazolyl, 1,3-thiazolyl, 1,2,5-thiadiazolyl, and 1,3-oxazolyl,
(a) the Het(Ar) ring is optionally substituted with 1-2 groups selected from —NC, C1-6 alkyl, —C0-4 alkylene-C3-6 cycloalkyl, halo, CH2CF3, CHF2, CF3, CH2CHF2, C(OR)(CF3)2, C2-6 alkenyl, C2-6 alkynyl, —C0-4 alkylene-OR, —O—C2-4 alkylene-OR, —C0-4 alkylene-C(O)R, —C0-4 alkylene-C(O)OR, —C0-4 alkylene-C(O)NRaRb, —C0-4 alkylene-S(O)2NRaRb, —C0-4 alkylene-NRaC(O)—C1-4 alkyl, —C0-4 alkylene-NRaS(O)2—C1-4 alkyl, and —C0-4 alkylene-S(O)2—C1-4 alkyl; and,
(b) R is C1-4 alkyl.